Comments
Shilpa Medicare on Tuesday said it has received approval from the US health regulator for Irinotecan HCL injection, used for the treatment of certain kinds of cancers.
The company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL injection USP in the strengths 40 mg/2ml and 100 mg/5ml (20mg/ml) single dose vials, Shilpa Medicare said in a BSE filing.
Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum, the company added.
Quoting IQVIA MAT second quarter 2018 data, Shilpa Medicare said the US market for Irinotecan HCL is approximately $18 million. Shares of Shilpa Medicare were trading 3.80 per cent up at Rs 398.65 apiece on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.